Graham has been interested in the therapeutic potential of psychedelic drugs since the late 1990s. This naturally evolved from his early interest in the interpretation of dreams, hypnosis and psychoanalysis.
He qualified as a doctor in 2003 from the University of Birmingham and trained in psychiatry from 2006. In 2012, he was awarded an MSc in Neuroscience with distinction from Kings College London and focussed on the role of inflammation in the aetiology of depression. He worked as an NHS inpatient consultant psychiatrist from 2012 at Mill View Hospital in Hove and trained with Imperial College London in February 2018 to work as an assistant guide for the trial comparing psilocybin with escitalopram for depression.
In March 2019, he helped set up the Brighton Psychedelic Integration Circle and was instrumental in organising educational events around psychedelics at Brighton & Sussex Medical School later that year. In 2020, he decided to leave the NHS after 17 years to devote himself full-time to psychedelic therapy research.
He now works as the Study Psychiatrist for a trial investigating N,N-dimethyltryptamine (DMT) as a treatment for depression. He is also a member of the advisory council for the Institute of Psychedelic Therapy
Trial Psychiatrist – DMT for Depression (Hammersmith Medicines Research)Previous NHS Consultant Psychiatrist (8 years)
Collaborator with Imperial College London Psychedelic Research Group
Director of Clinical Psychiatry – Small Pharma (fully seconded to HMR)
Advisory Council and Chair of Academic Circle – The Institute of Psychedelic Therapy